Top

Published in:

Open Access 01-06-2013 | Original Article

High expression of cancer stem cell markers in cholangiolocellular carcinoma

Authors: Shuichi Iwahashi, Tohru Utsunomiya, Mitsuo Shimada, Yu Saito, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Yoshimi Bando

Published in: Surgery Today | Issue 6/2013

Abstract

Purpose

Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC.

Methods

The subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically.

Results

Histological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative.

Conclusion

CLC may have stronger features derived from HpSCs than an intermediate type of CHC.

Steiner PE. Carcinoma of liver in United State. Acta Unio Int Contra Cancrum. 1957;13:628–45.PubMed

Steiner PE, Higginson J. Cholangiolocellular carcinoma of the liver. Cancer. 1959;12:753–9.PubMedCrossRef

Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, et al. The canals of Hering and hepatic stem cells in humans. Hepatology. 1999;30:1425–33.PubMedCrossRef

Tickoo SK, Zee SY, Obiekwe S, Xiao H, Koea J, Robiou C, et al. Combined hepatocellular cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989–97.PubMedCrossRef

Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892–7.PubMedCrossRef

Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996;11:758–64.PubMedCrossRef

Robrechts C, De Vos R, Van den Heuvel M, Van Cutsem E, Van Damme B, Desmet V, et al. Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver. 1998;18:288–93.PubMed

Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, et al. Primary liver carcinoma of intermediate (hepatocyte–cholangiocyte) phenotype. J Hepatol. 2004;40:298–304.PubMedCrossRef

Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med. 2007;204:1973–87.PubMedCrossRef

10.

Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–12.PubMed

11.

Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells. 2003;21:506–8.PubMedCrossRef

12.

Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973–8.PubMedCrossRef

13.

Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells. 2006;24:1852–8.PubMedCrossRef

14.

Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA. 2006;103:9912–7.PubMedCrossRef

15.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012–24.PubMedCrossRef

16.

Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008;98:1389–97.PubMedCrossRef

17.

Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol. 2010;45:896–902.PubMedCrossRef

18.

Cho CH, Parashurama N, Park EY, Suganuma K, Nahmias Y, Park J, et al. Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: applications for the treatment of liver failure. FASEB J. 2008;22:898–909.PubMedCrossRef

19.

Waclawczyk S, Buchheiser A, Flögel U, Radke TF, Kögler G. In vitro differentiation of unrestricted somatic stem cells into functional hepatic-like cells displaying a hepatocyte-like glucose metabolism. J Cell Physiol. 2010;225:545–54.PubMedCrossRef

20.

Shiota K, Taguchi J, Nakashima O, Nakashima M, Kojiro M. Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep. 2001;8:263–8.PubMed

21.

Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cells origin. Hepatology. 2008;47:1544–56.PubMedCrossRef

22.

Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004;39:1739–45.PubMedCrossRef

23.

Sell S. Liver stem cells. Mod Pathol. 1994;7:105–12.PubMed

24.

Evarts RP, Nagy P, Marsden E, Thorgeirsson SS. A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis. 1987;8:1727–40.CrossRef

25.

Yasui O, Miura N, Terada K, Kawarada Y, Koyama K, Sugiyama T. Isolation of oval cells from Long-Evans rats and their transformation into hepatocytes in vivo in the rat liver. Hepatology. 1997;24:329–34.

26.

Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998;29:455–63.PubMedCrossRef

27.

Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003;23:385–96.PubMedCrossRef

28.

Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25:3818–22.PubMedCrossRef

29.

Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52:280–1.PubMedCrossRef

30.

Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953–62.PubMedCrossRef

31.

Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, et al. Isolation and characterization of a stem cell population from adult human liver. Stem Cells. 2006;24:2840–50.PubMedCrossRef

32.

Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126:2067–78.PubMedCrossRef

33.

Kossatz U, Breuhahn K, Wolf B, Hardtke-Wolenski M, Wilkens L, Steinemann D, et al. The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J Clin Invest. 2010;120:3820–33.PubMedCrossRef

Title: High expression of cancer stem cell markers in cholangiolocellular carcinoma
Authors: Shuichi Iwahashi
Tohru Utsunomiya
Mitsuo Shimada
Yu Saito
Yuji Morine
Satoru Imura
Tetsuya Ikemoto
Hiroki Mori
Jun Hanaoka
Yoshimi Bando
Publication date: 01-06-2013
Publisher: Springer Japan
Published in: Surgery Today / Issue 6/2013
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-012-0437-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High expression of cancer stem cell markers in cholangiolocellular carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2013

Cytopathological review of patients that underwent thyroidectomies based on the diagnosis of papillary thyroid carcinoma by fine needle aspiration cytology but were later found to have benign tumors by histopathology

Regulatory T cells in the blood: a new marker of surgical stress

Ganglioneuroma in the papilla of Vater with neurofibromatosis type 1: report of a case

The management of a remnant pancreatic stump for preventing the development of postoperative pancreatic fistulas after distal pancreatectomy: current evidence and our strategy

Pancreaticoduodenectomy can be safely performed in the elderly

Visualization of diffusion of the drug solution during aluminum potassium tannic acid injection therapy: a pilot study